We postulated that CD24 blockage with a monoclonal antibody targeting CD24 could have anti-tumor therapeutic benefits while preserving a good safety profile and synergistic therapeutic effects when used in conjunction with other anti-tumor antibodies. This evidence concerns the gene CD24 and neoplasm.